Introduction to our 6-part series highlighting recent publications and posters in selected application areas.

At INOVOTION, we are proud to contribute to the transformation of preclinical cancer research through our validated CAM (ChorioAllantoic Membrane) model – a fast, cost-effective, and 3Rs-compliant in vivo platform for oncology drug development.

Over the coming weeks, we’ll be sharing a series of posts exploring the peer-reviewed articles and posters that highlight the breadth and depth of scientific studies performed using our CAM model.

Each post will focus on a specific application area, showing how the CAM model provides translational insights in:

• Angiogenesis
• Immuno-oncology, including CAR-T cells and checkpoint inhibitors
• Mechanisms of Action
• Metastases
• RNA Therapeutics
• Patient-Derived Avatars

Backed by a strong portfolio of scientific publications, conference presentations, and posters (American Association for Cancer Research (AACR), European Association for Cancer Research (EACR), etc.), these results demonstrate that the CAM model is not just an ethical NAMs alternative. It is a reliable, biologically relevant tool for preclinical screening and early-stage decision making.

Whether you are exploring immune-based therapies, novel small molecules, or RNA technologies, this series will provide insight into how the CAM assay has been rigorously tested across multiple oncology R&D settings.

Follow us to discover how leading biotech and pharma companies use the CAM model to accelerate and de-risk their oncology pipelines – with robust, reproducible data.

Learn more about our platform: https://www.inovotion.com

Reach out to schedule a meeting with our scientific team or learn more at: https://www.inovotion.com/contact